Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals. The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world. Read More
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.8% above analysts’ consensus estimates.
Profitability is a key measure of business strength.
Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.8% above analysts’ consensus estimates.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.
